| 产品编号 | bs-0318R |
| 英文名称 | PADI4 Rabbit pAb |
| 中文名称 | 关节炎相关基因抗体 |
| 别 名 | EC 3.5.3.15; HL 60 PAD; HL-60 PAD; PAD 4; PAD; PADI 4; PADI 5; PADI H protein; PADI5; PDI 4; PDI 5; PDI4; PDI5; Padi4; PADI4_HUMAN; Peptidyl arginine deiminase type IV; Peptidyl arginine deiminase type V; Peptidylarginine deiminase IV; Protein arginine de |
| 研究领域 | 免疫学 染色质和核信号 信号转导 新陈代谢 表观遗传学 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, |
| 产品应用 | ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 74 kDa |
| 检测分子量 | |
| 细胞定位 | 细胞核 细胞浆 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human PADI4: 401-500/663 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
PADI4 (peptidyl arginine deiminase, type IV) catalyzes the deimination of arginine residues of proteins. Down-regulates histone H3 and H4 arginine methylation, both by preventing arginine methylation by CARM1 and HRMT1L2/PRMT1 and by converting methylarginine to citrulline. subcellular location at cytoplasmic granules. Belongs to the protein arginine deiminase family. This gene may play a role in granulocyte and macrophage development leading to inflammation and immune response. Function: Catalyzes the citrullination/deimination of arginine residues of proteins. Citrullinates histone H3 at 'Arg-8' and/or 'Arg-17' and histone H4 at 'Arg-3', which prevents their methylation by CARM1 and HRMT1L2/PRMT1 and represses transcription. Citrullinates EP300/P300 at 'Arg-2142', which favors its interaction with NCOA2/GRIP1. Subcellular Location: Cytoplasm. Nucleus. Cytoplasmic granule. Note=Cytoplasmic granules of eosinophils and neutrophils. Tissue Specificity: Expressed in eosinophils and neutrophils, not expressed in peripheral monocytes or lymphocytes. Post-translational modifications: Autocitrullination at Arg-372 and Arg-374 inactivates the enzyme. DISEASE: Rheumatoid arthritis (RA) [MIM:180300]: An inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Note=The gene represented in this entry may be involved in disease pathogenesis. It could play a role in increasing citrullination of proteins in rheumatoid arthritis synovial tissues, leading, in a cytokine-rich milieu, to a break in tolerance to citrullinated peptides processed and presented in the appropriate HLA context. Similarity: Belongs to the protein arginine deiminase family. SWISS: Q9UM07 Gene ID: 23569 Database links: Entrez Gene: 23569 Human Omim: 605347 Human SwissProt: Q9UM07 Human Unigene: 522969 Human PADI4或称PAD4 (Protein-arginine deiminase type IV) 是关节炎相关基因，分子量为：74kDa。有学者认为：PADI4也称Ⅳ型肽基精氨酸脱氨酶，该蛋白与关节炎的发生关系密切。PADI4 基因能够合成一种酶，将精氨酸变为桔霉素，当含桔霉素蛋白质的数量超过正常标准后，人体血液中便会出现攻击含桔霉素的蛋白质的抗体，这种机理是导致关节炎的重要因素之一。 |
| 产品图片 |
Paraformaldehyde-fixed, paraffin embedded (human breast); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (PADI4) Polyclonal Antibody, Unconjugated (bs-0318R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
